FY2025 EPS Estimates for Genmab A/S Raised by William Blair

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Stock analysts at William Blair lifted their FY2025 earnings per share (EPS) estimates for shares of Genmab A/S in a report issued on Friday, November 7th. William Blair analyst M. Phipps now forecasts that the company will earn $1.97 per share for the year, up from their prior forecast of $1.75. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. William Blair also issued estimates for Genmab A/S’s Q4 2025 earnings at $0.47 EPS and FY2028 earnings at $2.74 EPS.

Several other research analysts have also issued reports on GMAB. Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price on the stock in a report on Tuesday, September 23rd. HC Wainwright reissued a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Finally, Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $28.66 on Monday. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $33.65. The firm has a market cap of $18.40 billion, a PE ratio of 12.20, a price-to-earnings-growth ratio of 1.56 and a beta of 0.96. The firm’s fifty day moving average is $29.61 and its 200-day moving average is $24.49.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 24.48%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $975.40 million. Genmab A/S has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Jones Financial Companies Lllp increased its holdings in Genmab A/S by 29.1% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock worth $57,000 after purchasing an additional 440 shares in the last quarter. Osaic Holdings Inc. boosted its position in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares during the last quarter. CWM LLC grew its holdings in Genmab A/S by 28.3% during the third quarter. CWM LLC now owns 2,306 shares of the company’s stock worth $71,000 after buying an additional 509 shares in the last quarter. Captrust Financial Advisors grew its holdings in Genmab A/S by 2.4% during the second quarter. Captrust Financial Advisors now owns 22,442 shares of the company’s stock worth $464,000 after buying an additional 526 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Genmab A/S by 3.2% in the 1st quarter. Rhumbline Advisers now owns 16,956 shares of the company’s stock valued at $332,000 after buying an additional 532 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.